CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on March 5, 2008
Clin J Am Soc Nephrol 3: 836-843, 2008
© 2008 American Society of Nephrology
doi: 10.2215/CJN.02910707
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.02910707v1
3/3/836    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raggi, P.
Right arrow Articles by Kleerekoper, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raggi, P.
Right arrow Articles by Kleerekoper, M.

Mini-Review

Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease

Paolo Raggi*, and Michael Kleerekoper{dagger}

* Department of Medicine and Radiology, Emory University School of Medicine, Atlanta, Georgia; and {dagger} Department of Endocrinology, Saint Joseph Mercy Hospital, Ann Arbor, and Department of Internal Medicine, Wayne State University, Detroit, Michigan

Correspondence: Dr. Paolo Raggi, Emory University School of Medicine, 1365 Clifton Road NE, AT-504, Atlanta, GA 30322. Phone: 404-778-5414; Fax: 404-778-3540; E-mail: praggi{at}emory.edu

1,25-Dihydroxyvitamin D3 levels begin to drop early in the course of kidney disease, leading to elevated parathyroid hormone levels and disrupted mineral metabolism. Impaired mineral metabolism seems to be associated not only with bone disease but also with vascular calcification. Animal models have identified molecular mechanisms by which high mineral levels and other uremic substances induce vascular smooth muscle cells to undergo phenotypic changes that initiate the calcification process. Moreover, several epidemiologic and clinical studies showed strong associations between bone loss, arterial calcification, and cardiovascular disease in populations with and without kidney disease. This review discusses evidence that two early complications of chronic kidney disease—vitamin D deficiency and secondary hyperparathyroidism—contribute to bone and cardiovascular disease. New treatment strategies aimed at the prevention of bone loss and parathyroid hyperplasia, such as vitamin D receptor ligand therapy, calcimimetic agents, and noncalcifying phosphate binders, are being investigated for their impact on improving overall outcome in dialysis patients.




This article has been cited by other articles:


Home page
 CJASNHome page
L. C. Plantinga, N. E. Fink, J. Coresh, S. M. Sozio, R. S. Parekh, M. L. Melamed, N. R. Powe, and B. G. Jaar
Peripheral Vascular Disease-Related Procedures in Dialysis Patients: Predictors and Prognosis
Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1637 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1506 - 1523.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. B. Drueke
Arterial Intima and Media Calcification: Distinct Entities with Different Pathogenesis or All the Same?
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1583 - 1584.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Nephrology.